Related references
Note: Only part of the references are listed.The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
Andrew G. Nicholson et al.
JOURNAL OF THORACIC ONCOLOGY (2022)
NRF2-GPX4/SOD2 axis imparts resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer cells
Chun-shuang Ma et al.
ACTA PHARMACOLOGICA SINICA (2021)
Cholesterol synthesis disruption combined with a molecule-targeted drug is a promising metabolic therapy for EGFR mutant non-small cell lung cancer
Youli Luo et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2021)
Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib
Zhen Chen et al.
ONCOGENE (2021)
Targeting AKR1B1 inhibits glutathione de novo synthesis to overcome acquired resistance to EGFR-targeted therapy in lung cancer
Ke-Ren Zhang et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Blocking Aerobic Glycolysis by Targeting Pyruvate Dehydrogenase Kinase in Combination with EGFR TKI and Ionizing Radiation Increases Therapeutic Effect in Non-Small Cell Lung Cancer Cells
Sissel E. Dyrstad et al.
CANCERS (2021)
Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent Resistance
Xu Zhang et al.
CANCER RESEARCH (2021)
Liquid chromatography-mass spectrometry based metabolic characterization of pleural effusion in patients with acquired EGFR-TKI resistance
Na Li et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2021)
3P AZ12756122, a novel fatty acid synthase (FASN) inhibitor, reduces resistance properties in gefitinib- and osimertinib-resistant EGFR-mutated non-small cell lung cancer models
E. Polonio et al.
Journal of Thoracic Oncology (2021)
Lipidomics reveals that sustained SREBP-1-dependent lipogenesis is a key mediator of gefitinib-acquired resistance in EGFR-mutant lung cancer
Chuncao Xu et al.
CELL DEATH DISCOVERY (2021)
Estimated Projection of US Cancer Incidence and Death to 2040
Lola Rahib et al.
JAMA NETWORK OPEN (2021)
Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors
Xiaojing Du et al.
INNOVATION (2021)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Reprogramming of fatty acid metabolism in cancer
Nikos Koundouros et al.
BRITISH JOURNAL OF CANCER (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Statins use and its impact in EGFR-TKIs resistance to prolong the survival of lung cancer patients: A Cancer registry cohort study in Taiwan
Phung-Anh Nguyen et al.
CANCER SCIENCE (2020)
Heterogeneity of Glucose Transport in Lung Cancer
Cesar A. Martinez et al.
BIOMOLECULES (2020)
Mechanisms of osimertinib resistance and emerging treatment options
Sabine Schmid et al.
LUNG CANCER (2020)
1,25-dihydroxyvitamin D3 signaling-induced decreases in IRX4 inhibits NANOG-mediated cancer stem-like properties and gefitinib resistance in NSCLC cells
Zhirong Jia et al.
CELL DEATH & DISEASE (2020)
Transcriptome Profiling of Acquired Gefitinib Resistant Lung Cancer Cells Reveals Dramatically Changed Transcription Programs and New Treatment Targets
Nan Wei et al.
FRONTIERS IN ONCOLOGY (2020)
The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism
Gerta Hoxhaj et al.
NATURE REVIEWS CANCER (2020)
Discovering the anticancer potential of non-oncology drugs by systematic viability profiling
Steven M. Corsello et al.
NATURE CANCER (2020)
1α,25-Dihydroxyvitamin D3 restrains stem cell-like properties of ovarian cancer cells by enhancing vitamin D receptor and suppressing CD44
Mintao Ji et al.
ONCOLOGY REPORTS (2019)
Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer
Nan Jin et al.
NATURE COMMUNICATIONS (2019)
Branched-Chain Amino Acid Metabolic Reprogramming Orchestrates Drug Resistance to EGFR Tyrosine Kinase Inhibitors
Yuetong Wang et al.
CELL REPORTS (2019)
The ERK and JNK pathways in the regulation of metabolic reprogramming
Salvatore Papa et al.
ONCOGENE (2019)
Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas
Hui-Min Lei et al.
THERANOSTICS (2019)
CAV1-GLUT3 signaling is important for cellular energy and can be targeted by Atorvastatin in Non-Small Cell Lung Cancer
Azhar Ali et al.
THERANOSTICS (2019)
miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma
Wen Cai Zhang et al.
NATURE METABOLISM (2019)
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer
Azhar Ali et al.
EMBO MOLECULAR MEDICINE (2018)
Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer
Shang-Gin Wu et al.
MOLECULAR CANCER (2018)
Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies
Maria Apicella et al.
CELL METABOLISM (2018)
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T79OM-Positive Lung Cancer and Acquired Resistance to Osimertinib
Geoffrey R. Oxnard et al.
JAMA ONCOLOGY (2018)
LBA51Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
V A Papadimitrakopoulou et al.
ANNALS OF ONCOLOGY (2018)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Statin improves survival in patients with EGFR-TKI lung cancer: A nationwide population-based study
Ming-Szu Hung et al.
PLOS ONE (2017)
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Ping Wee et al.
CANCERS (2017)
Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming
Praveena S. Thiagarajan et al.
ONCOTARGET (2016)
Lipidomic Profiling of Lung Pleural Effusion Identifies Unique Metabotype for EGFR Mutants in Non-Small Cell Lung Cancer
Ying Swan Ho et al.
SCIENTIFIC REPORTS (2016)
Fundamentals of cancer metabolism
Ralph J. DeBerardinis et al.
SCIENCE ADVANCES (2016)
The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Kristine Raaby Jakobsen et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2016)
Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib
Shinsuke Hashida et al.
CANCER SCIENCE (2015)
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih-Hsin Yang et al.
LANCET ONCOLOGY (2015)
First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
J-Y Douillard et al.
BRITISH JOURNAL OF CANCER (2014)
Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing?
Lucia Kim et al.
EUROPEAN RESPIRATORY JOURNAL (2014)
Epidermal Growth Factor Receptor ( EGFR) Signaling Regulates Global Metabolic Pathways in EGFR-mutated Lung Adenocarcinoma
Hideki Makinoshima et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
GLUT3 is induced during epithelial-mesenchymal transition and promotes tumor cell proliferation in non-small cell lung cancer
Mark Masin et al.
CANCER & METABOLISM (2014)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Share Paper
